RIPK2 and inflammatory breast carcinoma: Therefore, loss of RASSF1A in IBC may be an interesting marker for increased inflammation via hyperactive RIPK2 and increased growth (via reduced tumor suppression due to increased methylation of RASSF1A) in IBC.